Chinese drug approval expected in 2010.
Beijing Med-Pharm and Shanghai Novartis Trading Limited, a subsidiary of Novartis, inked an exclusive agreement to register, market, and distribute Enablex®, which is used to treat symptoms of urinary incontinence, urgency, and urinary frequency related to an overactive bladder (OAB), in China.
Under the terms of the agreement, Beijing Med-Pharm is responsible for attaining China SFDA approval of Enablex, a process that is expected to last through 2010. Once approved, Beijing Med-Pharm will have the exclusive rights to sell, market, and distribute Enablex in China for 10 years.
